Form : Tablets
/ Pack : 10 X 15’s
/ Type : Alu Alu
Description : Pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease - Clin Exp Gastroenterol. 2010; 3: 11–16.
Description : Prucalopride is a novel enterokinetic agent. It is the first of a new generation of selective, high-affinity 5-HT4 receptor agonists. It stimulates colonic mass movements, which provide the main propulsive force for defecation. This drug, which has been developed for the treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief, stimulates gastrointestinal motility through its effects on 5-HT4 receptors.
No cardiovascular safety issues have arisen with Prucalopride treatment. Although further long-term and comparative data would be beneficial, prucalopride provides an additional treatment option for patients with CIC - Drugs .2016 Jan; 76(1):99-110.
Description : Prucalopride is a novel enterokinetic agent. It is the first of a new generation of selective, high-affinity 5-HT4 receptor agonists. It stimulates colonic mass movements, which provide the main propulsive force for defecation. This drug, which has been developed for the treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief, stimulates gastrointestinal motility through its effects on 5-HT4 receptors.
No cardiovascular safety issues have arisen with Prucalopride treatment. Although further long-term and comparative data would be beneficial, prucalopride provides an additional treatment option for patients with CIC - Drugs .2016 Jan; 76(1):99-110.
Composition : Esomeprazole 40mg GR + Levosulpiride 75mg PR
Form : Capsules
/ Pack : 1 X 10s
/ Type : AA
Description : The absolute bioavailability is 64% after a single dose of Esomeprazole 40mg and increases to 89% after repeated once daily administration with 97% plasma protein bound. Levosulpiride blocks the enteric dopamine (D2 ) receptors (both neuronal & muscular) and also acts as an agonist at serotonin (5-HT4 ) receptor. Both the above actions increase the release of acetylcholine (Ach). Ach increases GI peristalsis and also increases lower esophageal sphincter pressure thereby preventing reflux of GI contents towards esophagus.
Esomeprazole demonstrates significantly greater efficacy than omeprazole in the treatment of GERD patients with erosive esophagitis. The tolerability and safety of esomeprazole are comparable to that of omeprazole - The American J of Gastroenterology, Vol 96, Iss 3, Mar 2001, P. 656-665.
Levosulpiride is an effective and safe drug in the treatment of dysmotility-like functional dyspepsia and non-erosive reflux disease - Ther Clin Risk Manag. 2007 Mar; 3(1): 149–155.
Composition : Rabeprazole 20mg + Levo Sulpiride 75mg SR
Form : Tablets
/ Pack : 10 x 10’s
/ Type : ALU-ALU
Description : A prospective, open-label, multicenter design in 342 patients with dysmotility-like functional dyspepsia (n=279) and nonerosive reflux disease (n=63), who received levosulpiride 25 mg 3 times daily orally for 4 weeks. Individual symptoms (pain/discomfort, fullness, bloating, early satiety, pyrosis, regurgitation, and nausea/vomiting) and a global symptom score were assessed at 15, 30, and 60 days after starting treatment. Adverse events also were recorded. There were 151 men and 191 women (mean age 38.8 years) who referred dyspeptic symptoms for a mean of 10.2 (10.7) months. A total of 66.4% patients were treated with 75 mg/day levosulpiride and 33.6% with 50 mg/day. At the 15-day visit, a decrease greater than 50% in the global symptom score was observed. The frequency and intensity of individual symptoms showed a statistically significant decrease (p<0.001) at all visits compared with baseline. At the 30-day visit, all symptoms had almost disappeared, a trend that was maintained until the last visit. Treatment with levosulpiride was well tolerated and only 40 adverse events were recorded (galactorrhea 26.7%, somnolence 17.8%, fatigue 11.1%, headache 11.5%) and no patient had to abandon the study due to side effects. Conclusion: levosulpiride is an effective and safe drug in the treatment of dysmotility-like functional dyspepsia and non-erosive reflux disease- Ther Clin Risk Manag. 2007 March; 3(1): 149–155. Rabeprazole binds to and inactivates the H+/K+-ATPase of gastric parietal cells, causing inhibition of the proton pump that transports H+ into the gastric lumen, the final common step in gastric acid production. Rabeprazole is a prodrug and is converted to the active form in the acidic secretory canaliculi of parietal cells. Because the inhibition is irreversible, acid secretion is suppressed for 24 to 48 hours, until new proton pump molecules have been synthesized and transported to the cell membrane.
Form : Sugar Free solution
/ Pack : 1 X 450ml
/ Type : Pet Bottle
Description : Lactulose is being used since the 1950s. It is on the World Health Organization's List of Essential Medicines. Lactulose is a non-absorbable sugar used in the treatment of constipation and hepatic encephalopathy. Lactulose is also commonly given to elderly people who have diminished mental or physical capacity to have a daily bowel movement. It is the treatment of choice for constipation in rest homes both because of its effectiveness and its lack of side effects. Lactulose has a sweet taste that can be completely masked by mixing it with coffee, tea, fruit juice, produces results within 4 hours if taken on a daily basis. Lactulose is useful for treatment of hemorrhoids because it produces a soft bowel movement. Lactulose is considered a prebiotic because it modulates the beneficial bacterial flora of the gut and is considered a digestive aid. Modulation of gut flora presumably works by reducing potential pathogenic bacteria such as Escherichia coli and Staphylococcus species in stool, with increase in non-urease producing Lactobacillus limiting ammonia production. Moreover, lactulose is converted to lactic and acetic acid which results in acidification of colonic contents. The low pH decreases passive non-ionic diffusion of ammonia thus lowering its systemic concentration. Furthermore, with its prebiotic potential, lactulose also encourages growth of probiotic bacteria such as Bifidobacterium species that are known to have health-promoting effects.
Form : Sugar Free solution
/ Pack : 1 x 200ml
/ Type : Pet Bottle
Description : Lactulose is being used since the 1950s. It is on the World Health Organization's List of Essential Medicines. Lactulose is a non-absorbable sugar used in the treatment of constipation and hepatic encephalopathy. Lactulose is also commonly given to elderly people who have diminished mental or physical capacity to have a daily bowel movement. It is the treatment of choice for constipation in rest homes both because of its effectiveness and its lack of side effects. Lactulose has a sweet taste that can be completely masked by mixing it with coffee, tea, fruit juice, produces results within 4 hours if taken on a daily basis. Lactulose is useful for treatment of hemorrhoids because it produces a soft bowel movement. Lactulose is considered a prebiotic because it modulates the beneficial bacterial flora of the gut and is considered a digestive aid. Modulation of gut flora presumably works by reducing potential pathogenic bacteria such as Escherichia coli and Staphylococcus species in stool, with increase in non-urease producing Lactobacillus limiting ammonia production. Moreover, lactulose is converted to lactic and acetic acid which results in acidification of colonic contents. The low pH decreases passive non-ionic diffusion of ammonia thus lowering its systemic concentration. Furthermore, with its prebiotic potential, lactulose also encourages growth of probiotic bacteria such as Bifidobacterium species that are known to have health-promoting effects.
A Superior gastro-prokinetic agent of the benzamide class
Composition : Cinitapride 1mg
Form : Tablets
/ Pack : 10 x 10's
/ Type : ALU-ALU
Description : Cinitapride, either given alone or after co-administration with ketoconazole 200 mg b.i.d., had no effect on cardiac repolarization as measured by changes in the heart rate-corrected QT interval on the surface electrocardiogram - Drug Metab Dispos. 2007 Jul;35(7):1149-56.
After 4 weeks of treatment, the Global Index Score showed statistically significant reduction in 58 (48.92%) patients (p<0.01). Similar reduction (p<0.01) was seen in individual dyspepsia symptoms; early satiety, post-prandial fullness, and abdominal distension. The 7 point Likert's scale also showed similar improvement in subjective response (p<0.01).The quality of life also improved significantly at week 2 and 4 (p<0.01). No abnormal results were seen in vital signs, physical and laboratory examination except an unexplained rise in globulin level. Only one adverse event (sore throat) was reported during the study - J Pak Med Assoc. 2013 Jun; 63(6):747-51
View more products with following salts Cinitapride
Description : Aluminium hydroxide to form a coating over the inflamed gastric mucosa.
Magnesium hydroxide to counter-act constipating effects of Aluminium hydroxide. Oxetacaine to exert a prolonged topical anesthetic action.
Composition : Pantoprazole 40mg + Domperodone 30mg SR
Form : Capsules
/ Pack : 10’s
/ Type : ALU-ALU
Description : Pantoprazole: During the post-treatment phase, patients have significantly lower risk to relapse GERD. Digestion, 2007;75 Suppl 1:69-78. Epub 2007 May 4. Domparidone: Selective prokeinetic without Diarrhoea and Cardiotoxicity.
